Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials

Lung Cancer

Volumn 74, Issue 3, 2011, Pages 469-473

  Ku, Geoffrey Y ^a,b   Haaland, Benjamin A ^c   de Lima Lopes, Gilberto ^a,b  

^a Johns Hopkins Singapore   (Singapore)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Adenocarcinoma; Chemotherapy; Gefitinib; Meta analysis; Non small cell lung cancer; Randomized trial

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; PACLITAXEL;

ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG ERUPTION; FATIGUE; GENE MUTATION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; SURVIVAL ANALYSIS;

EID: 80052746384     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.04.008     Document Type: Article

References (26)

1. Karamouzis M.V., Grandis J.R., Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007, 298:70-82.
2. Yarden Y., Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988, 57:443-478.
3. Volm M., Rittgen W., Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 1998, 77:663-669.
4. Brabender J., Danenberg K.D., Metzger R., Schneider P.M., Park J., Salonga D., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001, 7:1850-1855.
5. Hirsch F.R., Varella-Garcia M., Bunn P.A., Di Maria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
6. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003, 21:2237-2246.
7. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
8. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22:777-784.
9. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22:785-794.
10. Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:3238-3247.
11. Gandara D.R., West H., Chansky K., Davies A.M., Lau D.H., Crowley J., et al. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res 2004, 10. 4205s-4209s.
12. Janne P.A., Gurubhagavatula S., Yeap B.Y., Lucca J., Ostler P., Skarin A.T., et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, " Iressa" ) on an expanded access study. Lung Cancer 2004, 44:221-230.
13. West H.L., Franklin W.A., McCoy J., Gumerlock P.H., Vance R., Lau D.H., et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006, 24:1807-1813.
14. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
15. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
16. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
17. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
18. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
19. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
20. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
21. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
22. Lee J.S., Park K., Kim S.W., Lee D.H., Kim H.T., Han J.Y., et al. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 2009, 4. PRS 4 [abstr].
23. Yang C.H., Fukuoka M., Mok T.S., Wu Y.L., Thongprasert S., Saijo N., et al. Final overall survival (OS) results from a phase III, randomised, open-label, first-line study of gefitinib (g) v carboplatin/paclitaxel (c/p) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). Ann Oncol 2010, 21. LBA 2 [abstr].
24. Mok T.S., To K.F., Srimunimimit V., Chao T.Y., Ichinose Y., Wu Y.L., et al. Clinical outcomes of patients with epidermal growth factor receptor (EGFR) mutations (Mut) in IPASS (IRESSATM Pan ASia Study). J Thorac Oncol 2009, 4. B9.5 [abstr].
25. Piedbois P., Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol 2004, 22:3839-3841.
26. Leidner R.S., Fu P., Clifford B., Hamdan A., Jin C., Eisenberg R., et al. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol 2009, 27:5620-5626.